samfiodiving , really ?"29 May 2019 Updated Investor...

samfiodiving , really ?

"29 May 2019 Updated Investor PresentationAntisense Therapeutics (“ANP” or the “Company”) is pleased to provide an updated Investor Presentation incorporating the latest progress as recently announced on its ATL1102 for Duchenne Muscular Dystrophy Phase II clinical trial being conducted at the Royal Children’s Hospital in Melbourne. Further, the Company confirms that the dosing of the final two patients into the trial has now commenced."

The Company expects to report trial results shortly after the completion of dosing, though as previously advised, as the Phase II DMD clinical trial is an open label study there may be an opportunity for study non statistical read-outs on preliminary data prior to the completion of dosing in all patients. This would require a sufficient number of patients to have completed 24 weeks of dosing and for all patients to have passed at least the mid-point (12 week) dosing mark for the Company to be confident and certain of the robustness of such results for disclosure.